We inform you that on this website we use our own and third-party cookies to collect information about its use, improve our services and, where appropriate, display advertising by analyzing your browsing habits. You can expressly accept its use by pressing the "ACCEPT" button or configure and select the cookies you want to accept or reject in the settings. You can also get more information about our cookie policy here.

The global fashion business journal

Jun 13, 20244:59pm

Estée Lauder finalizes acquisition of Dr. Jart+ owner

The American beauty group, Estée Lauder, continues its Korean cosmetic pursuit with the recent acquisition of Dr. Jart Owner.

Dec 18, 2019 — 4:23pm


Estée Lauder finalizes acquisition of Dr. Jart+ owner



Estée Lauder announced today that it has finalized its acquisition of Have&Be, the Seoul-based international skincare company that also markets Dr. Jart+ and the men’s grooming brand Do The Right Thing.


Founded in 2005 by Chinwook Lee in Seoul, South Korea, Dr. Jart+ specializes in skincare, with a combination of dermatological science and art – as mirrored in the brands name. Which sourced its name from “Doctor Joins Art” – Dr. Jart+ attracts a broad range of consumers and has loyal followership among millennials in Asia and the United States.


Known for its premium, on-trend skincare collections such as Cicapair and Ceramidin, the brand is known for its rapid speed-to-market capabilities. Sold through specialty-multi channels, travel, retail, freestanding stores, high-end department stores and ecommerce sites in more than 35 countries worldwide.

The Estée Lauder Companies is one of the world’s largest manufacturers and marketers of skin care, makeup, fragrance and hair care products. The company’s products are sold in over 150 countries and territories under various brand names. Estée Lauder ended its 2018 fiscal year on a positive note, with net earnings increase of 17%, 448 million euros, compared to gain in 2017, 383 million euros. 

Participation rules



Validation policy for comments: 

MDS does not perform prior verification for the publication of comments. However, to prevent anonymous comments from affecting the rights of third parties without the ability to reply, all comments require a valid email address, which won’t be visible or shared.
Enter your name and email address to be able to comment on this news: once you click on the link you will find within your verification email, your comment will be published.

0 comments — Be the first to comment